Tianzhen Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tianzhen Wang has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Lirui Yang
Department of Pathology Harbin Medical University Harbin China
2 shared publicationsCiaran M. Fairman
Exercise Science Department, Arnold School of Public Health, University of South Carolina, Columbia, SC, USA
1 shared publication- Daniel Abido Galvao
Exercise Medicine Research Institute Edith Cowan University Joondalup Western Australia Australia
1 shared publication - Dennis R. Taaffe
Exercise Medicine Research Institute Edith Cowan University Joondalup Western Australia Australia
1 shared publication Fuqiang Bai
Department of Pathology Harbin Medical University Harbin China
1 shared publication- Hao Luo
Exercise Medicine Research Institute, Edith Cowan University, Joondalup, WA, Australia
1 shared publication
Latest Publications
- 16 March 2022
- Published by Wiley in Cell Biology International
- Vol. 46 (6) , 965-975
ARID3A promotes the chemosensitivity of colon cancer by inhibiting AKR1C3
ARID3A is upregulated in colorectal cancer and can promote the proliferation and metastasis of cancer cells. However, patients with higher level of ARID3A have a better prognosis. This study aimed to uncover the mechanism by which ARID3A benefits the prognosis of colon cancer. Our results indicated that ARID3A upregulation enhanced the chemosensitivity of colon cancer cells to 5‐fluorouracil (5‐FU), whereas ARID3A downregulation inhibited the chemosensitivity of colon cancer cells to 5‐FU. Through database analysis, we found that AKR1C3, a drug resistance‐related gene, was the target of ARID3A. Moreover, AKR1C3 was downregulated in colon cancer tissues compared to normal tissues. Next, we assessed the interaction between AKR1C3 and ARID3A, and found that ARID3A inhibited the transcription of AKR1C3, leading to the downregulation of AKR1C3 in colon cancer cells. We also verified that AKR1C3 inhibited the chemosensitivity of colon cancer cells to 5‐FU. Moreover, patients with higher ratio of ARID3A to AKR1C3 had a better prognosis. This study suggested that ARID3A promoted chemosensitivity of colon cancer cells by inhibiting AKR1C3 in colon cancer. The ratio of ARID3A to AKR1C3 is a good marker to predict the prognosis of colon cancer patients.
- 16 March 2022
- Published by Wiley in Cell Biology International
- Vol. 46 (6) , 965-975
ARID3A promotes the chemosensitivity of colon cancer by inhibiting AKR1C3
ARID3A is upregulated in colorectal cancer and can promote the proliferation and metastasis of cancer cells. However, patients with higher level of ARID3A have a better prognosis. This study aimed to uncover the mechanism by which ARID3A benefits the prognosis of colon cancer. Our results indicated that ARID3A upregulation enhanced the chemosensitivity of colon cancer cells to 5‐fluorouracil (5‐FU), whereas ARID3A downregulation inhibited the chemosensitivity of colon cancer cells to 5‐FU. Through database analysis, we found that AKR1C3, a drug resistance‐related gene, was the target of ARID3A. Moreover, AKR1C3 was downregulated in colon cancer tissues compared to normal tissues. Next, we assessed the interaction between AKR1C3 and ARID3A, and found that ARID3A inhibited the transcription of AKR1C3, leading to the downregulation of AKR1C3 in colon cancer cells. We also verified that AKR1C3 inhibited the chemosensitivity of colon cancer cells to 5‐FU. Moreover, patients with higher ratio of ARID3A to AKR1C3 had a better prognosis. This study suggested that ARID3A promoted chemosensitivity of colon cancer cells by inhibiting AKR1C3 in colon cancer. The ratio of ARID3A to AKR1C3 is a good marker to predict the prognosis of colon cancer patients.
- 7 January 2022
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 170, 103578
Protective effects of physical activity in colon cancer and underlying mechanisms: A review of epidemiological and biological evidence
- 7 January 2022
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 170, 103578
Protective effects of physical activity in colon cancer and underlying mechanisms: A review of epidemiological and biological evidence